Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Add as a preferred source on Google
AstraZeneca's suspension of global trials of its coronavirus vaccine dubbed AZD1222 triggered a 2 percent drop in its shares in London and a 12 plunge in the stock price of its Indian unit, AstraZeneca Pharma India Ltd.
The company is developing the AZD1222 vaccine with the University of Oxford.
The suspension, which dimmed the company's prospect of an early rollout, was necessary to review safety data after an unexplained illness in a participant.
AstraZeneca said that the suspension was routine every time there is a potentially unexplained illness in the trials.
The company is working to expedite the review to minimize any potential impact on the trial timeline.
The decision on restarting the trial will be taken by the medical regulator, the MHRA, that would take only days.
According to a New York Times report, citing a person familiar with the situation, the UK-based participant was found to have transverse myelitis, an inflammation that affects the spinal cord and is often sparked by viral infections.
Whether the condition was directly linked to AZD1222 remains unclear.
The AZD1222 has been described by the World Health Organization (WHO) as probably the world’s leading and the most advanced vaccine.
The vaccine is in late-stage clinical trials in the US, the UK, Brazil, and South Africa.
Additional trials are planned in Russia and Japan, targetting up to 50,000 participants globally.
The participant's reaction to AZD1222 has impacted clinical trials by other vaccine makers, which are on the lookout for similar reactions.
